At the same time, there has been a growth in understanding of the detailed immunophenotypes associated with the diagnostic entities of the WHO classification. In many cases it is now possible to make a firm diagnosis based on immunophenotypic criteria alone and this provides a very effective check on the accuracy of a morphologically based diagnosis. One of the weaknesses of the WHO classification is that although many of the entities can be diagnosed accurately and reproducibly, they are also highly heterogeneous with respect to clinical behaviour and response to treatment.
This means that in many cases, the routine immunophenotypic analysis of lymphoproliferative disorders needs to be extended to include prognostic markers that can be used to stratify patients according to their likely response to treatment. As more therapeutic monoclonal antibodies enter clinical practice, it will become important to assess accurately the extent of expression of cellular targets both at presentation and relapse. It is also becoming clear that in many cases, the immunophenotype is predictive of the presence of specific cytogenetic abnormalities.
This can be useful Forgot Password? What is MyAccess?
Pop-up div Successfully Displayed This div only appears when the trigger link is hovered over. Otherwise it is hidden from view. Forgot Username? About MyAccess If your institution subscribes to this resource, and you don't have a MyAccess Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Sign in via OpenAthens. Sign in via Shibboleth.
This, the seventh volume in the New Clinical Applications Series, has an international flavour, with contributions from Australia (Mr N.e. Davis), Great Britain (Drs. townrecmocoma.tk - Buy Tumours, Lymphomas and Selected Paraproteinaemias (New Clinical Applications: Dermatology) book online at best prices in India on.
AccessBiomedical Science. AccessEmergency Medicine. Case Files Collection. Clinical Sports Medicine Collection. Davis AT Collection.
Davis PT Collection. Murtagh Collection. About Search. Enable Autosuggest. Previous Chapter. Next Chapter. Jack A. USA ; 3 Another useful target for breast cancer therapy is the LIV-1 antigen described by Taylor et al.
For multiple myeloma therapy, suitable targeting antibodies have been described against, for example, CD38 and CD Stevenson, Mol Med ; 12 ; Tassone et al. Macrophage migration inhibitory factor MIF is an important regulator of innate and adaptive immunity and apoptosis. The therapeutic effect of antagonistic anti-CD74 antibodies on MIF-mediated intracellular pathways may be of use for treatment of a broad range of disease states, such as cancers of the bladder, prostate, breast, lung, colon and chronic lymphocytic leukemia e.
Checkpoint inhibitor antibodies have been used primarily in cancer therapy. Immune checkpoints refer to inhibitory pathways in the immune system that are responsible for maintaining self-tolerance and modulating the degree of immune system response to minimize peripheral tissue damage. However, tumor cells can also activate immune system checkpoints to decrease the effectiveness of immune response against tumor tissues.
Exemplary checkpoint inhibitor antibodies against cytotoxic T-lymphocyte antigen 4 CTLA-4, also known as CD , programmed cell death protein 1 PD-1, also known as CD and programmed cell death 1 ligand 1 PD-L1, also known as CD , may be used in combination with one or more other agents to enhance the effectiveness of immune response against disease cells, tissues or pathogens.
Ipilimumab has recently received FDA approval for treatment of metastatic melanoma Wada et al.
See, e. Gynecol Oncol ; ; Boiire D, et al.
In another preferred embodiment, antibodies are used that internalize rapidly and are then re-expressed, processed and presented on cell surfaces, enabling continual uptake and accretion of circulating conjugate by the cell. The CD74 antigen is highly expressed on B-cell lymphomas including multiple myeloma and leukemias, certain T-cell lymphomas, melanomas, colonic, lung, and renal cancers, glioblastomas, and certain other cancers Ong et al. A review of the use of CD74 antibodies in cancer is contained in Stein et al. Where bispecific antibodies are used, the second MAb may be selected from any anti-hapten antibody known in the art, including but not limited to h U.
Antibodies of use may be commercially obtained from a wide variety of known sources.
www.hiphopenation.com/mu-plugins/usa/best-new-free-dating-apps.php These are exemplary only and a wide variety of other antibodies and their hybridomas are known in the art. The antigen binding domains of the cloned antibodies may be amplified, excised, ligated into an expression vector, transfected into an adapted host cell and used for protein production, using standard techniques well known in the art. Antibody fragments which recognize specific epitopes can be generated by known techniques.
An antibody fragment can be prepared by proteolytic hydrolysis of the full length antibody or by expression in E. These methods are described, for example, by Goldenberg, U. Also, see Nisonoff et al. The V L and V H domains associate to form a target binding site. These two domains are further covalently linked by a peptide linker L. Methods for making scFv molecules and designing suitable peptide linkers are described in U. Raag and M. Bird and B.
An scFv library with a large repertoire can be constructed by isolating V-genes from non-immunized human donors using PCR primers corresponding to all known V H , V kappa and V 80 gene families. Following amplification, the V kappa and V lambda pools are combined to form one pool. These fragments are ligated into a phagemid vector. The scFv linker is then ligated into the phagemid upstream of the V L fragment.
The resulting V H -linker-V L fragments are ligated into a phagemid vector. The phagemid library can be panned for binding to the selected antigen. Other antibody fragments, for example single domain antibody fragments, are known in the art and may be used in the claimed constructs. Single domain antibodies VHH may be obtained, for example, from camels, alpacas or llamas by standard immunization techniques.
The VHH may have potent antigen-binding capacity and can interact with novel epitopes that are inaccessible to conventional VH-VL pairs. Muyldermans et al. Alpacas may be immunized with known antigens and VHHs can be isolated that bind to and neutralize the target antigen Maass et al. PCR primers that amplify virtually all alpaca VHH coding sequences have been identified and may be used to construct alpaca VHH phage display libraries, which can be used for antibody fragment isolation by standard biopanning techniques well known in the art Maass et al.
These and other known antigen-binding antibody fragments may be utilized in the claimed methods and compositions. Various techniques, such as production of chimeric or humanized antibodies, may involve procedures of antibody cloning and construction. To confirm their authenticity, the cloned V L and V H genes can be expressed in cell culture as a chimeric Ab as described by Orlandi et al.
Based on the V gene sequences, a humanized MAb can then be designed and constructed as described by Leung et al. BioTechniques , Hybridoma, Humanized V genes can be constructed by a combination of long oligonucleotide template syntheses and PCR amplification as described by Leung et al.
The expression vectors can be co-transfected into an appropriate cell and supernatant fluids monitored for production of a chimeric, humanized or human MAb. Methods and also shown in Losman et al. In an alternative embodiment, expression vectors may be transfected into host cells that have been pre-adapted for transfection, growth and expression in serum-free medium. In certain embodiments, the techniques and compositions for therapeutic agent delivery disclosed herein may be used with bispecific or multispecific antibodies as the targeting moieties.
Numerous methods to produce bispecific or multispecific antibodies are known, as disclosed, for example, in U. Bispecific antibodies can be produced by the quadroma method, which involves the fusion of two different hybridomas, each producing a monoclonal antibody recognizing a different antigenic site Milstein and Cuello, Nature, ; Another method for producing bispecific antibodies uses heterobifunctional cross-linkers to chemically tether two different monoclonal antibodies Staerz, et al.
Bispecific antibodies can also be produced by reduction of each of two parental monoclonal antibodies to the respective half molecules, which are then mixed and allowed to reoxidize to obtain the hybrid structure Staerz and Bevan. Other methods include improving the efficiency of generating hybrid hybridomas by gene transfer of distinct selectable markers via retrovirus-derived shuttle vectors into respective parental hybridomas, which are fused subsequently DeMonte, et al.
Delecluse, H. In certain embodiments, treatment may be enhanced by combination therapy with one or more other therapeutic agents. Methods for obtaining human antibodies from transgenic mice are disclosed by Green et al. The landscaped antibodies were subsequently reacted with agents comprising a ketone-reactive moiety, such as hydrazide, hydrazine, hydroxylamino or thiosemicarbazide groups, to form a labeled targeting molecule. Another useful target for breast cancer therapy is the LIV-1 antigen described by Taylor et al.
Cognate V H and V L domains can be joined with a peptide linker of appropriate composition and length usually consisting of more than 12 amino acid residues to form a single-chain Fv scFv with binding activity. Methods of manufacturing scFvs are disclosed in U. Reduction of the peptide linker length to less than 12 amino acid residues prevents pairing of V H and V L domains on the same chain and forces pairing of V H and V L domains with complementary domains on other chains, resulting in the formation of functional multimers. Polypeptide chains of V H and V L domains that are joined with linkers between 3 and 12 amino acid residues form predominantly dimers termed diabodies.
With linkers between 0 and 2 amino acid residues, trimers termed triabody and tetramers termed tetrabody are favored, but the exact patterns of oligomerization appear to depend on the composition as well as the orientation of V-domains V H -linker-V L or V L -linker-V H , in addition to the linker length. These techniques for producing multispecific or bispecific antibodies exhibit various difficulties in terms of low yield, necessity for purification, low stability or the labor-intensiveness of the technique.
The technique utilizes complementary protein binding domains, referred to as anchoring domains AD and dimerization and docking domains DDD , which bind to each other and allow the assembly of complex structures, ranging from dimers, trimers, tetramers, quintamers and hexamers. These form stable complexes in high yield without requirement for extensive purification.
The DNL technique allows the assembly of monospecific, bispecific or multispecific antibodies. Any of the techniques known in the art for making bispecific or multispecific antibodies may be utilized in the practice of the presently claimed methods. In various embodiments, a conjugate as disclosed herein may be part of a composite, multispecific antibody. Such antibodies may contain two or more different antigen binding sites, with differing specificities. The multispecific composite may bind to different epitopes of the same antigen, or alternatively may bind to two different antigens.
In preferred embodiments, bispecific or multispecific antibodies or other constructs may be produced using the dock-and-lock technology see, e. Wong and Scott, Nat.